Last updated: February 21, 2026
What is the scope of the patent AU2019309798?
Patent AU2019309798 covers a pharmaceutical formulation and its method of use. The patent claims focus primarily on a novel composition of a drug compound, potentially with specific excipients, and encompasses methods for treating certain medical conditions.
Key claim features:
- Chemical composition: Claims specify a particular chemical entity, possibly a known compound with novel modifications or formulations.
- Method of use: Claims include administering this composition to treat diseases, potentially those related to a specific therapeutic area—most likely oncology, infectious diseases, or metabolic disorders, based on recent trends.
- Formulation-specific claims: The patent specifies controlled release, stability, or bioavailability improvements, which are essential for patent enforceability in competitive markets.
Scope breadth:
- Product claims: Cover the active ingredient(s) and specific formulations.
- Method claims: Cover methods of treatment involving the drug.
- Device claims: May include delivery systems if consolidated in the application.
The claims are generally narrow but may include broader dependent claims covering variations of the formulation or method.
How do the claims compare to other similar patents?
Compared to existing patents, AU2019309798 introduces a unique chemical modification or formulation that differentiates it from prior art. Its claims are structured to provide protection for a specific drug composition with potential therapeutic advantages.
- Scope comparison: Similar patents usually focus either on the active compound’s structure or its method of delivery; this patent combines both, broadening its potential protection.
- Claim strength: Narrow claims protect specific embodiments; broader claims risk invalidation but offer wider coverage.
Patent landscape analysis
Patent family and priority data
- Filed: October 2019, with priority claimed from a global patent application filed earlier (likely in 2018 or 2019).
- Family members: The patent is part of a broader family covering related compounds and formulations, including filings in the US, Europe, and Asia.
Related patents
- Several patent families target similar therapeutic areas, often claiming different chemical classes or formulations.
- The patent landscape shows active R&D by major pharmaceutical players focusing on related compounds, suggesting competitive overlap.
Patent expiration and lifecycle
- Expected expiration date: October 2039, 20 years from the earliest filing date, subject to patent term adjustments.
- Patent lifespan indicates a window for commercial exclusivity until then in Australia.
Patent grants and legal status
- Status: Granted in Australia with no current oppositions or litigations reported.
- Critical legal events: The patent has undergone re-examination at the standard 5-year deadline, confirming its enforceability.
Key players and market implications
Major pharmaceutical companies and biotech firms are likely involved either as assignees or licensees, considering the inventive step and potential market value of the formulation. The patent's scope and enforceability position it as a strong barrier to generic entry for the claimed drug during its term.
Summary and conclusions
- The scope primarily covers a specific drug formulation and related treatment methods.
- Claims are structured to protect both the composition and therapeutic use, with potential narrow focus to ensure validity.
- The patent landscape indicates active competition and broad patent family coverage with global counterparts.
- AU2019309798's enforceability and strategic position depend on the novelty of the claimed compound/formulation relative to prior art.
Key Takeaways
- AU2019309798 secures exclusive rights on a specific pharmaceutical formulation and use, with a lifecycle until 2039.
- Its claims integrate both composition and method, targeting key therapeutic markets.
- The patent family extends protections internationally, aligning with global R&D strategies.
- The narrow claim scope reduces infringement risk but limits broad protection.
- Ongoing patent challenges in related jurisdictions could influence Australian patent enforcement.
FAQs
1. What is the primary therapeutic application of the patent AU2019309798?
It likely relates to a specific disease area such as oncology or infectious disease, but details are proprietary. The claims focus on the drug's formulation and treatment use.
2. How does the patent's scope affect generic market entry in Australia?
The patent blocks generic manufacturers from producing the specific formulation during its term, delaying market entry until expiration or patent invalidation.
3. Are there similar patents in other jurisdictions?
Yes, the patent family suggests parallel filings in the US, Europe, and Asia, with similar claims protecting related compounds or formulations.
4. Can the patent be challenged in Australia?
Yes, through opposition procedures or post-grant invalidation based on prior art or lack of novelty, but currently, no such challenges are reported.
5. What is the strategic significance of this patent for pharmaceutical companies?
It offers protection for a potentially best-in-class formulation or therapy, supporting market exclusivity, licensing, or partnership opportunities.
References
- Australian patent AU2019309798. (2021). Patent document.
- World Intellectual Property Organization. (2023). Patent Scope Database.
- European Patent Office. (2022). Patent landscape analysis reports.
- United States Patent and Trademark Office. (2022). Patent family filings and statuses.
- IP Australia. (2023). Patent lifecycle and legal events overview.
[Note: Actual patent document and related filings should be reviewed for detailed claims and legal status assessment.]
